Amniotic membrane preparations and purified compositions and anti-inflammation methods
Inventors
Tseng, Scheffer • He, Hua • Li, Wei
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-9750771-B2
Publication Date
2017-09-05
Expiration Date
Abstract
Compositions having a combination of specific biological components have been found to exert a number of useful effects in mammalian cells, including modulating TGF β signaling, apoptosis, and proliferation of mammalian cells, as well as decreasing inflammation in mice. These components can be obtained commercially, or can be prepared from biological tissues such as placental tissues. Placental amniotic membrane (AM) preparations described herein include AM pieces, AM extracts, AM jelly, AM stroma, and mixtures of these compositions with additional components. The compositions can be used to treat various diseases, such as wound healing, inflammation and angiogenesis-related diseases.
Core Innovation
The invention relates to amniotic membrane preparations and administering a water-soluble extract derived from frozen or previously frozen placenta. The water-soluble extract comprises tumor necrosis factor-stimulated gene 6 (TSG-6), pentraxin (PTX-3), thrombospondin (TSP-1), and cross-linked high molecular weight hyaluronan (HA). The disclosed approach is positioned as reducing inflammation in a subject in need thereof through administration of the specified AM-derived composition.
A purified anti-inflammatory composition is described that includes cross-linked high molecular weight HA together with TSG-6, PTX-3, and TSP-1. The preparation emphasizes obtaining or extracting these components from frozen placenta, amniotic membrane, amniotic jelly, or amniotic stroma, and analyzing the presence of HA-related complexes such as HA-inter-α-trypsin inhibitor. The disclosed formulation link is made to anti-inflammatory and anti–TGF-β effects.
The document connects the composition to suppression of TGF-β1 promoter activity dependent on HA-related complexes, with loss of this suppression after hyaluronidase digestion. It further describes macrophage responses, including changes in macrophage NO, PGD2, and PGE2, and increased macrophage apoptosis under IFN-γ stimulation. Overall, the core concept is an AM water-soluble extract containing TSG-6, PTX-3, TSP-1, and cross-linked high molecular weight HA, associated with reduced inflammatory activity and altered TGF-β signaling-related outcomes.
Claims Coverage
The independent claim is directed to a method of reducing inflammation by administering an AM water-soluble extract from frozen or previously frozen placenta. The coverage includes four main specified inventive components in the water-soluble extract: TSG-6, PTX-3, TSP-1, and cross-linked high molecular weight hyaluronan (HA).
Administering an amniotic membrane water-soluble extract from frozen placenta to reduce inflammation
A method of reducing inflammation in a subject in need thereof by administering a composition comprising a water-soluble extract of amniotic membrane from frozen or previously frozen placenta.
Composition with TSG-6, PTX-3, TSP-1, and cross-linked high molecular weight hyaluronan
The water-soluble extract comprises tumor necrosis factor-stimulated gene 6 (TSG-6), pentraxin (PTX-3), thrombospondin (TSP-1), and cross-linked high molecular weight hyaluronan (HA).
The claims coverage centers on reducing inflammation through administration of a water-soluble amniotic membrane extract obtained from frozen or previously frozen placenta, with the extract containing TSG-6, PTX-3, TSP-1, and cross-linked high molecular weight hyaluronan. Dependent claim refinements focus on which inflammatory disorders are treated and on additional formulation and administration details.
Stated Advantages
Reduces inflammation in a subject in need thereof.
Associated with anti-inflammatory effects and anti–TGF-β effects, including suppression of TGF-β1 promoter activity dependent on HA-related complexes.
Documented Applications
Treating ocular inflammation, including by ocular administration routes described in the dependent claim summaries.
Treating skin inflammation disorders and gastrointestinal disorders, including disorders enumerated in the dependent claim summaries (e.g., psoriasis, eczema, burns, dermatitis; and inflammatory bowel disease, peptic ulcers, Crohn’s disease, gastritis, diarrhea, ulcerative colitis, gastroparesis, food allergies and intolerances).
Treating inflammation associated with a variety of inflammatory conditions and disorders enumerated in the dependent claim summaries, including arthritis and non-cardiac chest pain.
Interested in licensing this patent?